Warfarin regimens (targeted INR < 2.0) have been investigated and found to be safe in the primary prevention of thrombosis in patients with malignancy. In two randomized trials in patients with malignancy, warfarin therapy, 1 mg/d of warfarin and 1 mg/d for 6 weeks followed by adjustment to an INR of 1.3 to 1.9, did not increase the frequency […]
-
Archives
- June 2016
- February 2016
- September 2015
- February 2015
- November 2014
- October 2014
- September 2014
- August 2014
- June 2014
- April 2014
- May 2013
- January 2013
- December 2012
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010